of physician organizations have opposed the pricing policy of the company as did the March of Dimes that supported the arrival of Makena. The FDA commissioner Margaret Hamburg stated that the agency was not in a position to influence pricing. Concerned about price gouging, two Senators, Amy Klobuchar (D-Minn.) and Sherrod Brown (D-Ohio) indicated that they plan to initiate hearings with the Federal Trade Commission about KV's conduct. The controversy spawned protests like the "Shame on You KV Pharmaceutical and CEO Greg Divis" Facebook page. By the end of March the FDA announced that pharmacies compounding the drug independently will not face legal reprisal, thus enabling the price of the drug to remain in the $10–20 range. After this announcement, K-V's stock dropped by more than 60% on March 30, 2011, and the company cut the price of Makena to $690 per dose. Bankruptcy and acquisition KV Pharmaceutical filed a petition for protection under Chapter 11 of the Bankruptcy Act on August 4, 2012 in U.S. Bankruptcy Court for the Southern District of New York in Manhattan. The petition listed the company’s assets as $237 million and its debts as $728 million. The filing came on the same day that the company failed to make a $95 million payment it owed to Hologic Inc., KV’s partner in developing Makena. The bankruptcy followed a long string of troubles for KV involving oversize morphine tablets, a criminal prosecution, and the barring of KV’s former chairman, Marc Hermelin, from doing business with federal health programs. The company emerged from bankruptcy in 2013 with less debt and a $375 million recapitalization, including cancellation of its previous preferred and common stock. Senior secured notes were paid in cash, and general unsecured creditors received a pro rata share of $10.25 million. Convertible subordinated noteholders received 7 percent of KV’s new common shares in addition to shares purchased through the rights offering or direct purchase of shares. The company changed its name to Lumara Health, Inc. in May, 2014 and in September, 2014 announced that it was being acquired by two different buyers in deals valued at $757 million. Waltham, Massachusetts-based AMAG Pharmaceuticals acquired Lumara Health for $675 million in cash and stock, and in a separate transaction, Dublin, Ireland-based Perrigo Co. acquired Lumara Health’s women’s health care business, including the Clindesse Vaginal Cream, Gynazole-1 and Evamist products, for $82 million. The AMAG Pharmaceuticals acquisition included the